Proliferative effects of insulin analogues on mammary epithelial cells

References

• Bähr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997; 320: 259–265
   PubMed Web of Science ®Google Scholar
• Bi R C, Dauter Z, Dodson E, Dodson G, Giordano F, Reynolds C. Insulin's structure as a modified and monomeric molecule. Biopolymers 1984; 23: 391–395
   Web of Science ®Google Scholar
• Blundell T, Dodson G G, Cutfield J M, Cutfield S M. Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 1972; 26: 279–402
   Google Scholar
• Bornfeldt K E, Gidlöf R A, Wasteson A, Lake M, Skottner A, Arnqvist H J. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 1991; 34: 307–313
   PubMed Web of Science ®Google Scholar
• Ciaraldi T P, Carter L, Seipke G, Mudaliar S, Henry R R. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001; 86: 5838–5847
   PubMed Web of Science ®Google Scholar
• Del Giudice M E, Fantus I G, Ezzat S, McKeown-Eyssen G, Page D, Goodwin P J. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998; 47: 111–120
   PubMed Web of Science ®Google Scholar
• Dideriksen L H, Jorgensen L N, Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin B10SP. Abstract. Diabetes 1992; 41: 143A
   Google Scholar
• Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 1992; 8: 259–285
   PubMed Web of Science ®Google Scholar
• Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001; 54: 149–154
   PubMedGoogle Scholar
• Fawcett J, Hamel F G, Bennett R G, Vajo Z, Duckworth W C. Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity. J Biol Chem 2001; 276: 11552–11558
   PubMed Web of Science ®Google Scholar
• Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings B A. Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase – significance for diabetes and cancer. Pharmacol Ther 1999; 82: 409–425
   PubMed Web of Science ®Google Scholar
• Gammeltoft S. Insulin receptors: binding kinetics and structure-function relationship of insulin. Physiol Rev 1984; 64: 1321–1378
   PubMed Web of Science ®Google Scholar
• Gammeltoft S, Hansen B F, Dideriksen L, Lindholm A, Schäffer L, Trüb T, Dayan A, Kurtzhals P. Insulin aspart: a novel rapid-acting human insulin analogue. Exp Opin Invest Drugs 1999; 8: 1–11
   PubMedGoogle Scholar
• Hankinson S E, Willet W C, Colditz G A, Hunter D J, Michaud D S, Deroo B, Rosner B, Speizer F E, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393–1396
   PubMed Web of Science ®Google Scholar
• Hansen B F, Danielsen G M, Drejer K, Sørensen A R, Wiberg F C, Klein H H, Lundemose A G. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996; 315: 271–279
   PubMed Web of Science ®Google Scholar
• Jackson J G, White M F, Yee D. Insulin receptor substrate-1 is the predominant signalling molecule activated by insulin-like growth factor-I, insulin and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 1998; 273: 9994–10003
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005
   PubMed Web of Science ®Google Scholar
• LeRoith D, Werner H, Beitner-Johnson D, Roberts C T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Rev 1995; 16: 153–163
   Google Scholar
• LeRoith D. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev 2007; 23: 593–599
   PubMed Web of Science ®Google Scholar
• Milazzo G, Sciacca L, Papa V, Goldfine I D, Vigneri R. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 1997; 18: 19–25
   PubMed Web of Science ®Google Scholar
• Nakagawa S H, Tager H S. Role of the COOH-terminal B-chain domain in insulin receptor interactions. Identification of perturbations involving the insulin main chain. J Biol Chem 1987; 162: 12054–12058
   Google Scholar
• Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli G B, Brand R, Goldfine I D, Vigneri R. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503–1510
   PubMed Web of Science ®Google Scholar
• Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Res 1998; 152: 63–70
   PubMedGoogle Scholar
• Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 2003; 52: 2227–2238
   PubMed Web of Science ®Google Scholar
• Reed M J, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: An emerging hypothesis. Endocrine Rev 1997; 18: 701–715
   PubMed Web of Science ®Google Scholar
• Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. Downregulation of insulin-like growth factor-1 receptor and insulin receptor substrate-1 in advanced human breast cancer. Int J Cancer (Pred Oncol) 2000; 89: 506–513
   PubMed Web of Science ®Google Scholar
• Sellers T A, Anderson K E, Olson J E, Folsom A R. Family histories of diabetes mellitus and breast cancer and incidence of postmenopausal breast cancer. Epidemiology 1998; 9: 102–105
   PubMed Web of Science ®Google Scholar
• Slieker L J, Brooke G S, DiMarchi R D, Flora D B, Green L K, Hoffmann J A, Long H B, Fan L, Shields J E, Sundell K L, et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997; 40(Suppl 2)S54–S61
   PubMedGoogle Scholar
• Staiger K, Hennige A M, Staiger H, Häring H U, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007; 39: 65–67
   PubMed Web of Science ®Google Scholar
• Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002; 21: 171–179
   PubMed Web of Science ®Google Scholar
• Stammberger I, Seipke G, Bartels T. Insulin glulisine – A comprehensive preclinical evaluation. Int J Toxicol 2006; 25: 25–33
   PubMed Web of Science ®Google Scholar
• Surmacz E, Guvakova M A, Nolan M K, Nicosia R F, Sciacca L. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 1998; 47: 255–267
   PubMed Web of Science ®Google Scholar
• White M F, Yenush L. The IRS-signalling system: a network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol 1998; 228: 179–208
   PubMed Web of Science ®Google Scholar